TY - JOUR
AU - L . Y. Haque
AU - L. Leggio
A1 - 
AB - The public health impact of alcohol-associated liver disease (ALD), a serious consequence of problematic alcohol use, and alcohol use disorder (AUD) is growing, with ALD becoming a major cause of alcohol-associated death overall and the leading indication for liver transplantation in the United States. Comprehensive care for ALD often requires treatment of AUD. Although there is a growing body of evidence showing that AUD treatment is associated with reductions in liver-related morbidity and mortality, only a minority of patients with ALD and AUD receive this care. Integrated and collaborative models that streamline both ALD and AUD care for patients with ALD and AUD are promising approaches to bridge this treatment gap and rely on multidisciplinary and interprofessional teams and partnerships. Here, we review the role of AUD care in ALD treatment, the effects of AUD treatment on liver-related outcomes, the impact of comorbid conditions such as other substance use disorders, obesity, and metabolic syndrome, and the current landscape of integrated and collaborative care for ALD and AUD in various treatment settings. We further review knowledge gaps and unmet needs that remain, including the role of precision medicine, the application of harm reduction approaches, the impact of health disparities, and the need for additional AUD treatment options, as well as further efforts to support implementation and dissemination.
AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.; Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.; Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Providence, Rhode Island, USA.; Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.
AN - 38935926
BT - Hepatology
C5 - Opioids & Substance Use
CP - 6
DA - Dec 1
DO - 10.1097/hep.0000000000000996
DP - NLM
ET - 20240627
IS - 6
JF - Hepatology
LA - eng
N2 - The public health impact of alcohol-associated liver disease (ALD), a serious consequence of problematic alcohol use, and alcohol use disorder (AUD) is growing, with ALD becoming a major cause of alcohol-associated death overall and the leading indication for liver transplantation in the United States. Comprehensive care for ALD often requires treatment of AUD. Although there is a growing body of evidence showing that AUD treatment is associated with reductions in liver-related morbidity and mortality, only a minority of patients with ALD and AUD receive this care. Integrated and collaborative models that streamline both ALD and AUD care for patients with ALD and AUD are promising approaches to bridge this treatment gap and rely on multidisciplinary and interprofessional teams and partnerships. Here, we review the role of AUD care in ALD treatment, the effects of AUD treatment on liver-related outcomes, the impact of comorbid conditions such as other substance use disorders, obesity, and metabolic syndrome, and the current landscape of integrated and collaborative care for ALD and AUD in various treatment settings. We further review knowledge gaps and unmet needs that remain, including the role of precision medicine, the application of harm reduction approaches, the impact of health disparities, and the need for additional AUD treatment options, as well as further efforts to support implementation and dissemination.
PY - 2024
SN - 0270-9139 (Print); 0270-9139
SP - 1408
EP - 1423+
ST - Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
T1 - Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
T2 - Hepatology
TI - Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
U1 - Opioids & Substance Use
U3 - 10.1097/hep.0000000000000996
VL - 80
VO - 0270-9139 (Print); 0270-9139
Y1 - 2024
ER -